Whitepaper: Making MS-based glycan analysis easier
Posted: 4 March 2021 | Merck | No comments yet
Recent technological advances have made it easier to cope with the complexity of mass spectrometry (MS) based glycan analysis.
Glycosylation occurs in expression systems for producing biological drugs, creating a complex spectrum of N- and O-linked glycans that vary significantly with regards to in vivo stability, solubility, activity, safety, and efficacy. This makes glycoprotein analysis a challenging task that is performed at several levels: intact protein, subunit, peptide, and glycan. This white paper presents recent advances in MS-based methods to reduce the task’s complexity at all four levels.
Related content from this organisation
- Moderna-Merck & Co cancer vaccine with Keytruda shows late-stage promise
- Raman-based PAT tool could advance continuous vaccine manufacturing
- Merck acquires JSR Life Sciences chromatography business
- MSD acquisition to accelerate first-in-class COPD drug
- Next drug patent cliff to challenge Big Pharma strategy
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, QA/QC, Regulation & Legislation, Research & Development (R&D)
